The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X, BIOGEAS Study Group

Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.

The American journal of medicine. 2011;124(5):386-94

Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M

Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.

Seminars in arthritis and rheumatism. 2011;41(2):256-64

Thavarajah K, Wu P, Rhew EJ, Yeldandi AK, Kamp DW

Pulmonary complications of tumor necrosis factor-targeted therapy.

Respiratory medicine. 2009;103(5):661-9

Tournadre A, Ledoux-Eberst J, Poujol D, Dubost JJ, Ristori JM, Soubrier M

Exacerbation of interstitial lung disease during etanercept therapy: Two cases.

Joint bone spine. 2008;75(2):215-8

Yousem SA, Dacic S

Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2005;18(5):651-5

Peno-Green L, Lluberas G, Kingsley T, Brantley S

Lung injury linked to etanercept therapy.

Chest. 2002;122(5):1858-60